Interplay between fish oil, obesity and cardiometabolic diabetes

J Formos Med Assoc. 2023 Jul;122(7):528-539. doi: 10.1016/j.jfma.2023.03.013. Epub 2023 Mar 29.

Abstract

Diabetes, dyslipidemia, obesity, and cardiac dysfunction are the hallmarks of the cardiometabolic syndrome. Pathogens include hypercoagulability, inflammation, endothelial dysfunction, and oxidative stress. Increased white fat, nonalcoholic fatty liver disease, diabetes, and cardiovascular disease are caused by obesity. Depression increases the risk of future obesity, a surprising link between obesity and neuropathology. High glucose levels, abnormal lipids, and metabolic syndrome are the root causes of CVD associated with diabetes. Diets high in fat induce insulin resistance and liver fat. Inflammation, diminished insulin signaling, and ectopic lipid accumulation are the causes of ectopic lipid accumulation. Polyunsaturated fatty acids with eicosapentaenoic acid and docohexasonoic acid inhibit the synthesis of triglycerides and increase their clearance. Omega-3 regulates the nervous system, blood pressure, hematic clotting, glucose tolerance, and inflammation. However, anxiety and depression can cause cardiovascular disease. It has been shown that PUFAs found in fish oil can improve glucose and lipid metabolism, cardiac membrane composition, and inflammation in the body. By repairing the dysregulation of metabolic syndrome, fish oil is a potential therapeutic target for cardiovascular diseases.

Keywords: Cardiometabolic; Diabetes; Fish oil; Inflammation; Obesity.

Publication types

  • Review

MeSH terms

  • Cardiovascular Diseases* / complications
  • Cardiovascular Diseases* / prevention & control
  • Diabetes Mellitus*
  • Fish Oils / therapeutic use
  • Glucose
  • Humans
  • Inflammation / complications
  • Metabolic Syndrome* / complications
  • Obesity / complications

Substances

  • Fish Oils
  • Glucose